Search Results - "Valimaki, M. J."

One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel by Caron, Ph, Bex, M., Cullen, D. R., Feldt-Rasmussen, U., Pico Alfonso, A. M., Pynka, S., Racz, K., Schopohl, J., Tabarin, A., Valimaki, M. J.

“…Summary objective  Somatostatin analogue treatment is first‐line medical therapy for acromegaly. This study compared the efficacy and tolerability of titrated…”
Get full text

Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decades by Dinneen, S F, Valimaki, M J, Bergstralh, E J, Goellner, J R, Gorman, C A, Hay, I D

“…The present study was designed to define the factors that predict survival in patients with distant metastases (DM) from papillary thyroid carcinoma. We…”
Get more information

Postoperative zoledronic acid for osteoporosis in primary hyperparathyroidism: a randomized placebo-controlled study by Ryhänen, E M, Koski, A M, Löyttyniemi, E, Välimäki, M J, Kiviniemi, U, Schalin-Jäntti, C

“…Objective In primary hyperparathyroidism (PHPT) with osteoporosis, bone mineral density (BMD) improves after parathyroidectomy. It is unclear whether combining…”
Get full text

Childhood growth predicts higher bone mass and greater bone area in early old age: findings among a subgroup of women from the Helsinki Birth Cohort Study by Mikkola, T. M., von Bonsdorff, M. B., Osmond, C., Salonen, M. K., Kajantie, E., Cooper, C., Välimäki, M. J., Eriksson, J. G.

“…Summary We examined the associations between childhood growth and bone properties among women at early old age. Early growth in height predicted greater bone…”
Get full text

Bone material properties and response to teriparatide in osteoporosis due to WNT1 and PLS3 mutations by Fratzl-Zelman, Nadja, Wesseling-Perry, Katherine, Mäkitie, Riikka E., Blouin, Stéphane, Hartmann, Markus A., Zwerina, Jochen, Välimäki, Ville-Valtteri, Laine, Christine M., Välimäki, Matti J., Pereira, Renata C., Mäkitie, Outi

“…Patients with osteoporosis-associated WNT1 or PLS3 mutations have unique bone histomorphometric features and osteocyte-specific hormone expression patterns. To…”
Get full text

A Novel Splice Mutation in PLS3 Causes X‐linked Early Onset Low‐Turnover Osteoporosis by Laine, Christine M, Wessman, Maija, Toiviainen‐Salo, Sanna, Kaunisto, Mari A, Mäyränpää, Mervi K, Laine, Tero, Pekkinen, Minna, Kröger, Heikki, Välimäki, Ville‐Valtteri, Välimäki, Matti J, Lehesjoki, Anna‐Elina, Mäkitie, Outi

“…ABSTRACT Genetic factors play an important role in the development of osteoporosis. Several monogenic forms of osteoporosis have been recognized, most recently…”
Get full text

Osteocyte Protein Expression Is Altered in Low-Turnover Osteoporosis Caused by Mutations in WNT1 and PLS3 by Wesseling-Perry, Katherine, Mäkitie, Riikka E., Välimäki, Ville-Valtteri, Laine, Tero, Laine, Christine M., Välimäki, Matti J., Pereira, Renata C., Mäkitie, Outi

“…Abstract Context: Osteocytes express proteins that regulate bone remodeling and mineralization. Objective: To evaluate the relationship between…”
Get full text

Teriparatide Treatment in Patients with WNT1 or PLS3 Mutation-Related Early-Onset Osteoporosis - A Pilot Study by Välimäki, Ville-Valtteri, Mäkitie, Outi, Pereira, Renata, Laine, Christine, Wesseling-Perry, Katherine, Määttä, Jorma, Kirjavainen, Mikko, Viljakainen, Heli, Välimäki, Matti J

“…Context: We previously identified two Finnish families with dominantly inherited, low-turnover osteoporosis caused by mutations in WNT1 or PLS3. Objective:…”
Get full text

Prevention of bone loss by clodronate in early postmenopausal women with vertebral osteopenia: a dose-finding study by Välimäki, M J, Laitinen, K, Patronen, A, Puolijoki, H, Seppänen, J, Pylkkänen, L, Aranko, Suvi-Marja, Sairanen, Sirpa, Blåfield, Harri, Rekiaro, Matti, Väisänen, Kari, Kormano, Martti, Mäkinen, Lasse, Salmi, Jorma, Ala-Kaila, Kyösti, Perttilä, Jyrki, Vesterinen, Kai, Koivunoro, Kalevi

“…This double-masked, placebo-controlled study was undertaken to determine the efficacy and safety of oral clodronate in the prevention of bone loss in early…”
Get full text

Exercise, smoking, and calcium intake during adolescence and early adulthood as determinants of peak bone mass by Valimaki, M J, Karkkainen, M, Lamberg-Allardt, C, Laitinen, K, Alhava, E, Heikkinen, J, Impivaara, O, Makela, P, Palmgren, J, Seppanen, R, Vuori, I

“…Objective: To evaluate the contribution to peak bone mass of exercise, smoking, and calcium intake in adolescents and young adults. Design: Prospective cohort…”
Get full text

Vitamin D fortification of milk products does not resolve hypovitaminosis D in young Finnish men by Valimaki, V.V, Loyttyniemi, E, Valimaki, M.J

“…Objective: To study if vitamin D fortification of milk products started in February 2003 has improved vitamin D status of young Finnish men, which has been…”
Get full text

Genetically defined adult-type hypolactasia and self-reported lactose intolerance as risk factors of osteoporosis in Finnish postmenopausal women by Enattah, N, Pekkarinen, T, Valimaki, M.J, Loyttyniemi, E, Jarvela, I

“…Objective: To study the relationships of molecularly defined lactose malabsorption (LM) and self-reported lactose intolerance (LI) to bone mineral density…”
Get full text

Efficacy and Safety of Prolonged-Release Lanreotide in Patients With Gastrointestinal Neuroendocrine Tumors and Hormone-Related Symptoms by WYMENGA, A. N. M, ERIKSSON, B, SALMELA, P. I, JACOBSEN, M. B, VAN CUTSEM, E. J. D. G, FIASSE, R. H, VÄLIMÄKI, M. J, RENSTRUP, J, DE VRIES, E. G. E, ÖBERG, K. E

“…To evaluate the prolonged release (PR) of the long-acting somatostatin analog lanreotide in patients with gastrointestinal neuroendocrine tumors and its effect…”
Get full text

Quantitative ultrasound variables of the heel in Finnish men aged 18-20 yr : predictors, relationship to bone mineral content, and changes during military service by VÄLIMÄKI, V.-V, LÖYTTYNIEMI, E, VÄLIMÄKI, M. J

“…Determinants of BUA and SOS and their changes during military service-associated physical training were studied in 196 army recruits and 50 control men, aged…”
Get full text

A prospective study of bone loss and turnover after allogeneic bone marrow transplantation : effect of calcium supplementation with or without calcitonin by VÄLIMÄKI, M. J, KINNUNEN, K, VOLIN, L, TÄHTELÄ, R, LÖYTTYNIEMI, E, LAITINEN, K, MÄKELÄ, P, KETO, P, RUUTU, T

“…Transplantation of solid organs including heart, kidney, and liver is associated with rapid bone loss and increased rate of fracture; data on bone marrow…”
Get full text

Serum tartrate-resistant acid phosphatase 5b in monitoring bisphosphonate treatment with clodronate : a comparison with urinary N-terminal telopeptide of type I collagen and serum type I procollagen amino-terminal propeptide by TÄHTELÄ, Riitta, SEPPÄNEN, J, LAITINEN, K, KATAJAMÄKI, A, RISTELI, J, VÄLIMÄKI, M. J

“…Osteoclastic tartrate-resistant acid phosphatase activity in serum (S-TRACP 5b) was measured in postmenopausal women ( n =59, mean age 56.1 years) with…”
Get full text

A high prevalence of hypovitaminosis D in Finnish medical in‐ and outpatients by Kauppinen‐Mäkelin, R., Tähtelä, R., Löyttyniemi, E., Kärkkäinen, J., Välimäki, M. J.

“… Kauppinen‐Mäkelin R, Tähtelä R, Löyttyniemi E, Kärkkäinen J, Välimäki MJ (Peijas Hospital, Vantaa; United Laboratories, Leiras Research, and Division of…”
Get full text

Recovery of bone mass and normalization of bone turnover in long-term survivors of allogeneic bone marrow transplantation by KANANEN, K, VOLIN, L, TÄHTELÄ, R, LAITINEN, K, RUUTU, T, VÄLIMÄKI, M. J

“…Osteoporotic fractures are potential long-term complications of bone marrow transplantation (BMT). We previously reported that bone mineral density (BMD) of…”
Get full text

Ovarian hyperstimulation caused by gonadotroph adenoma secreting follicle-stimulating hormone in 28-year-old woman by VÄLIMÄKI, M. J, TIITINEN, A, ALFTHAN, H, PAETAU, A, PORANEN, A, SANE, T, STENMAN, U.-H

“…Ovarian hyperstimulation caused by a gonadotroph adenoma in premenopausal women has been described only twice before this report. A 28-yr-old woman presented…”
Get full text

Effects of 42 months of GH treatment on bone mineral density and bone turnover in GH-deficient adults by VÄLIMÄKI, M. J, SALMELA, P. I, SALMI, J, VIIKARI, J, KATAJA, M, TURUNEN, H, SOPPI, E

“…To study the effects of GH treatment for up to 42 months on bone mineral density (BMD) and bone turnover. BMD with dual energy X-ray absorptiometry, serum type…”
Get full text